Literature DB >> 22653949

FCA: forget chemoimmunotherapy with alemtuzumab?

Michael Hallek1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22653949     DOI： 10.1182/blood-2012-04-413096

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.

Authors:  Jeremy L Warner; Jon E Arnason
Journal:  Ther Adv Hematol       Date:  2012-12

2.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.